Advertisement

Archives of Virology

, Volume 162, Issue 11, pp 3363–3370 | Cite as

Protective immune response of oral rabies vaccine in stray dogs, corsacs and steppe wolves after a single immunization

  • K. Zhugunissov
  • Ye. Bulatov
  • D. Taranov
  • Z. Yershebulov
  • Zh. Koshemetov
  • Ye. Abduraimov
  • Zh. Kondibayeva
  • A. Samoltyrova
  • Zh. Amanova
  • B. Khairullin
  • A. Sansyzbay
Original Article

Abstract

In this study the safety and protective immunity of an oral rabies vaccine, based on the live, modified rabies virus strain VRC-RZ2, was examined in stray dogs (Canis Sp.), corsacs (Vulpes corsac) and steppe wolves (Canis lupus campestris). In the safety group (dogs, n=6; corsacs, n=3; wolves, n=3) which was vaccinated with a 10-times field dose/animal, no animals showed any signs of disease or changes in behavior or appetite during the period of clinical observation, similar to the animals in the negative control group. Saliva samples taken from animals prior and post (5th and 10th days) vaccination failed to demonstrate rabies virus antigen. Observations of immunogenicity in vaccinated carnivores (dogs, corsacs and wolves) during a 180 day period showed the titers of virus neutralizing antibodies (VNA) in the blood sera of vaccinated dogs to be within 0.59-1.37 IU/mL. On 14 days post vaccination (dpv), all the wild carnivores had detectable levels of neutralizing antibodies, with mean titers ranging from 0.50 ± 0.07 IU/mL (for wolves) to 0.59 ± 0.10 IU/mL (for corsacs). Weeks after vaccination, all the vaccinated wolves and corsacs had higher levels of neutralizing antibodies: 0.70 ± 0.10 – 0.71 ± 0.08 IU/mL at 30 dpv, 1.06 ± 0.08 – 1.28 ± 0.21 IU/mL at 60 dpv and 0.41 ± 0.09 – 047 ± 0.06 at 180 dpv. The highest level of VNA (˃1.0 IU/ml) was detected at 60 dpv, in all vaccinated animals. After challenge all vaccinated dogs remained healthy for 180 days. Control animals (unvaccinated dogs) developed symptoms of rabies on day 6 post administration of a virulent virus and died of rabies on days 11-13. Of note, the VNA titers in all the wild carnivores (corsacs and wolves) immunized with VRC-RZ2 were higher than 0.5 IU/ml (0.59 ± 0.11 IU/ml), even as early as 14 days post vaccination. These, presumably protective, titers of antibodies to rabies virus were present in the dogs and wild carnivores examined in this study for at least 180 days.

Notes

Acknowledgements

The authors express their deep gratitude to the Deputy Director of the Almaty Zoo Azhibayev A. for implementation of the research; to the head of the laboratory at RIBSP, the Candidate of Biological Sciences, Dr. Koshemetov Zh.K., for performance of the serological study; to the Senior Researcher Strochkov V.M. for implementation of the molecular and genetic research; to the Candidate of Veterinary Sciences, Dr. Zhilin Ye.S. for advising; to Junior Researcher Dalbayev N.K., and to senior laboratory technicians Sametova Zh & Alimbayev Ye for implementation of the research. The work was carried out under the project 0114RK00100 “Development of complex preventive measures against wildlife animal diseases” as part of the research program O.0649 “Wildlife Monitoring for and Study of Dangerous Pathogens in the Regions of Current Epidemiological Interest and Development of Complex Preventive Measures for Providing Biological Safety in the Republic of Kazakhstan” for 2013–2015 funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan.

Compliance with ethical standards

Conflict of interest

Authors do not have any financial conflict of interests.

References

  1. 1.
    Gruzdev KN, Nedosekov VV (2001) Rabies of animals. Aquarium, Moscow (in Russian) Google Scholar
  2. 2.
    Moges N (2015) Epidemiology, prevention and control methods of rabies in domestic animals: review article. Eur J Biol Sci 7(2):85–90Google Scholar
  3. 3.
    Yousaf MZ, Qasim M, Zia S, Khan MR, Ashfaq UA, Rehman Khan S (2012) Rabies molecular virology, diagnosis, prevention and treatment. Virol J 9:50. doi: 10.1186/1743-422X-9-50 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Allendorf SD, Cortez A, Heinemannc MB et al (2012) Rabies virus distribution in tissues and molecular characterization of strains from naturally infected non-hematophagous bats. Virus Res 165:119–125CrossRefPubMedGoogle Scholar
  5. 5.
    Wandeler AI, Matter HC, Kappeler A, Budde A (1993) The ecology of dogs and canine rabies: a selective review. Rev Sci Tech Off Int Epizoot 12(1):51–71CrossRefGoogle Scholar
  6. 6.
    Krebs JW, Wilson ML, Childs JE (1995) Rabies-epidemiology, prevention, and future research. J Mammal 76(3):681–694CrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention (2014) Wildlife reservoirs for rabies. https://www.cdc.gov/rabies/exposure/animals/wildlife_reservoirs.html. Accessed 19 Aug 2016
  8. 8.
    Hooper DC, Roy A, Barkhouse DA, Li J, Kean RB (2011) Rabies virus clearance from the central nervous system. Adv Virus Res 79:55–71CrossRefPubMedGoogle Scholar
  9. 9.
    Mahyshev TA (2006) Modern features of the wild-type rabies and hydrophobia and questions eradication of rabies in Kazakhstan. In: A special edition of the third international conference. The state and prospects of development of veterinary biological preparations. Almaty, pp 309–312 (in Russian) Google Scholar
  10. 10.
    Yang D-K, Kim H-H, Lee K-W, Song J-Y (2013) The present and future of rabies vaccine in animals. Clin Exp Vaccine Res 2:19–25. doi: 10.7774/cevr.2013.2.1.19 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rupprecht CE, Hanlon CA, Slate D (2004) Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol (Basel) 119:173–184Google Scholar
  12. 12.
    Mähl P, Cliquet F, Guiot AL, Niin E, Fournials E, Saint-Jean N, Aubert M, Rupprecht ChE, Gueguen S. (2014) Twenty year experience of the oral rabies vaccine SAG2 in wildlife: a global review. Vet Res 45:77. http://www.veterinaryresearch.org/content/45/1/77
  13. 13.
    Cliquet F, Robardet E, Picard Meyer E (2013) Genetic strain modification of a live rabies virus vaccine widely used in Europe for wildlife oral vaccination. Antivir Res 100(1):84–89CrossRefPubMedGoogle Scholar
  14. 14.
    Curk A, Carpenter DTE (1994) Efficacy of the first oral vaccination against fox rabies in slovenia rev. Sci Tech Off Int Epizoot 13(3):763–775CrossRefGoogle Scholar
  15. 15.
    Cliquet F, Gurbuxani JP, Pradhan HK et al (2007) The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine 25:3409–3418CrossRefPubMedGoogle Scholar
  16. 16.
    Sterner RT,. Meltzer MI, Shwiff SA, Slate D (2009) Tactics and economics of wildlife oral rabies vaccination, Canada and the United States. Emerg Infect Dis 15(8): 1176–1184. http://www.cdc.gov/eid
  17. 17.
    Follmann E, Ritter D, Swor R, Dunbar M, Hueffer K (2011) Preliminary evaluation of raboral V-RG® oral rabies vaccine in arctic foxes (Vulpes lagopus). J Wildl Dis 47(4):1032–1035CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Scientific Panel on Animal Health and Welfare (AHAW) (2015) Update on oral vaccination of foxes and raccoon dogs against rabies. EFSA J 13(7):41–64Google Scholar
  19. 19.
    Mainguy J, Fehlner-Gardiner C, Slate D, Rudd RJ (2013) Oral rabies vaccination in raccoons: comparison of ONRAB® and RABORAL V-RG® vaccine-bait field performance in Québec, Canada and Vermont, USA. J Wildl Dis 49(1):190–193CrossRefPubMedGoogle Scholar
  20. 20.
    Vitasek J (2004) A review of rabies elimination in Europe. Vet Med (Czech Republic) 49(5):171–185Google Scholar
  21. 21.
    MacInnes CD, Smith SM, Tinline RR, Ayers NR, Bachmann P et al (2001) Elimination of rabies from red foxes in eastern Ontario. J Wildl Dis 37:119–132CrossRefPubMedGoogle Scholar
  22. 22.
    Rosatte RC, Power MJ, Donovan D, Davies JC, Allan M et al (2007) Elimination of arctic fox variant rabies in red foxes, metropolitan Toronto. Emerg Infect Dis 13:25–27CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nadin-Davis SA, Casey GA, Wandeler AI (2006) A molecular epidemiological study of rabies virus in central Ontario and western Quebec. J Gen Virol 75:2575–2583CrossRefGoogle Scholar
  24. 24.
    Rosatte RC, MacInnes CD, Williams RT, Williams O (1997) A proactive prevention strategy for raccoon rabies in Ontario, Canada. Wildl Soc B 25:110–116Google Scholar
  25. 25.
    Slate D, Rupprecht CE, Donovan D, Badcock J, Messier A et al (2008) Attaining raccoon rabies management goals: history and challenges. In: Dodet B, Fooks AR, Müller T, Tordo N, The Scientific and Technical Department of the OIE (eds) Towards the elimination of rabies in Eurasia, vol 131. pp 439–447Google Scholar
  26. 26.
    Aikymbayev A (2015) Rabies in Kazakhstan. In: 3rd Middle East & Eastern Europe Rabies Expert Bureau Meeting, 7–9 April 2015, Lyon, FranceGoogle Scholar
  27. 27.
    Committee on Consumers Protection in the Republic of Kazakhstan (2015) Rabies morbidity, (in Russian). http://kzpp.gov.kz/rus/presscentr/news/?cid=0&rid=1638. Accessed 16 Apr 16
  28. 28.
    Sultanov AA, Abdrakhmanov SK, Abdybekova AM, Karatayev BS, Torgerson PR (2016) Rabies in Kazakhstan. PLoS Negl Trop Dis 10(8):e0004889. doi: 10.1371/journal.pntd.0004889 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Buchnev KN, Rosliakov AA, Kvasov IL, Sedov VA (1976) Anti-rabies vaccine of the Alma-Ata Zooveterinary Institute. Veterinariia (8):45–46 (in Russian) Google Scholar
  30. 30.
    National Institute of Intellectual Property, Republican Governmental Enterprise of the Ministry of Justice, Republic of Kazakhstan. https://gosreestr.kazpatent.kz/ru/SearchPatent/SearchPatentIz/ViewPatentIz/138658?ElDossierTabId=NiisGosreestrDocs. Accessed  8 Apr 2016 (in Russian)
  31. 31.
    Zhilin YS, Russanova AM, Chervyakova OV, Troitskiy YN, Mamadaliyev SM (2006) Immunobiological characterization of the rabies virus strain VRC-RZ2 adapted to the continuous cell cultures of Syrian hamster kidney. In: Mat. international conference progress of international cooperation in study of infectious diseases, Ulianovsk, p 67 (in Russian) Google Scholar
  32. 32.
    Atanasin P (1973) Quantitative assay and potency test of antirabies serum and immunoglobulin. In: Kaplan M, Koprowski H (eds) Laboratory techniques in rabies, 3rd edn. WHO, Geneva, pp 314–318Google Scholar
  33. 33.
    Reed LJ, Muench H (1938) Simple method for estimating 50% end points. Am J Hyg 27:493–497Google Scholar
  34. 34.
    WHO (1995) Oral immunization of dogs against rabies. In: Report of the sixth WHO consultation (WHO/EMC/ZD/98.13). WHO, GenevaGoogle Scholar
  35. 35.
    Selimov MA (1978) Rabies. Medizdat, MoscowGoogle Scholar
  36. 36.
    Cliquet F, Aubert M (2004) Elimination of terrestrial rabies in Western European countries. In: Schudel A, Lombard M (eds) Control of infectious animal diseases by vaccination. Karger, Basel, pp 185–204Google Scholar
  37. 37.
    Pashala AA (1984) Accumulation of the fixed rabies virus in brain and pith of rabbits and sheep depending on methods of infection and disease stage. Dissertation, Alma-Ata, RussianGoogle Scholar
  38. 38.
    Orłowska A, Zmudzinski JF (2015) Genetic characterisation of the rabies virus vaccine strains used for oral immunization of foxes in Poland to estimate the effectiveness of vaccination. Arch Virol 160:509–515CrossRefPubMedGoogle Scholar
  39. 39.
    Vos A, Pommerening E, Neubert L, Kachel S, Neubert A (2002) Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J Wildl Dis 38(2):428–431CrossRefPubMedGoogle Scholar
  40. 40.
    Faber M, Dietzschold B, Li J (2009) Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife. Zoonoses Public Health 56(6–7):262–269CrossRefPubMedGoogle Scholar
  41. 41.
    Meslin FX, Kaplan MM, Koprowski H (eds) (1996) Laboratory techniques in rabies, 4th edn. WHO, GenevaGoogle Scholar
  42. 42.
    Matouch O, Vitasek J, Semerad Z, Malena M (2006) Elimination of rabies in the Czech Republic. Dev Biol (Basel) 125:141–143Google Scholar
  43. 43.
    Smith JS (1996) New aspects of rabies with emphasis on epidemiology, diagnosis, and prevention of the disease in the United States. Clin Microbiol Rev 9:166–176PubMedPubMedCentralGoogle Scholar
  44. 44.
    Zhilin YS (2013) Immunogenicity and safety of the rabies virus vaccine for oral administration based on the rabies virus strain VRC-RZ2 in Russian. Vestnik KNAU (Bulletin of Kaz.Nat.Agr.Univ.) 4:35–43Google Scholar
  45. 45.
    Gribencha SV, Selimov MA (1972) Effect of the site of rabies vaccine administration on immunity formation. Byulleten' Eksperimental'noi Biologii i Meditsiny 73(5):84–87 (in Russian) Google Scholar
  46. 46.
    Neubert A, Schuster P, Müller T, Vos A, Pommerening E (2001) Immunogenicity and efficacy of the oral rabies vaccine SAD B19 in foxes. J Vet Med B Infect Dis Vet Public Health 48(3):179–183CrossRefPubMedGoogle Scholar
  47. 47.
    Schneider LG (1995) Rabies virus vaccines. Dev Biol Stand 84:49–54PubMedGoogle Scholar
  48. 48.
    Zhesterev VI, Khripunov YeM. (2004) Rabies virus vaccines for oral application and their immunobiological characteristics. In: Wildlife diseases: proceedings of international science and practice conference GNU VNIIVViM. Pokrov, Russian, pp 154–58Google Scholar
  49. 49.
    Crepin PL, Audry Y (2012) Intravitam diagnosis of human rabies by PCR using saliva and cerebrospinal fluid. Pathol Int 62(9):619–627CrossRefGoogle Scholar
  50. 50.
    WHO (2007) Guidance for research on oral rabies vaccines and field application of oral vaccination of dogs against rabies, Geneva. http://www.who.int/rabies. Accessed  28 July 2017 

Copyright information

© Springer-Verlag GmbH Austria 2017

Authors and Affiliations

  • K. Zhugunissov
    • 1
  • Ye. Bulatov
    • 1
  • D. Taranov
    • 1
  • Z. Yershebulov
    • 1
  • Zh. Koshemetov
    • 1
  • Ye. Abduraimov
    • 1
  • Zh. Kondibayeva
    • 1
  • A. Samoltyrova
    • 1
  • Zh. Amanova
    • 1
  • B. Khairullin
    • 1
  • A. Sansyzbay
    • 1
  1. 1.Research Institute for Biological Safety ProblemsGuardeiskiyKazakhstan

Personalised recommendations